The impact of proteasome inhibition on alloantibody-producing plasma cells in vivo

Transplantation

Volumn 91, Issue 5, 2011, Pages 536-541

  Diwan, Tayyab S ^a   Raghavaiah, Suresh ^a   Burns, Justin M ^a   Kremers, Walter K ^a   Gloor, James M ^a   Stegall, Mark D ^a  

^a MAYO CLINIC   (United States)

Author keywords

Alloantibodies; Clinical kidney transplantation; Plasma cells; Proteasome inhibitor; Sensitized patients

Indexed keywords

ALLOANTIBODY; BORTEZOMIB; DONOR SPECIFIC ALLOANTIBODY; IMMUNOGLOBULIN G; PROTEASOME; TETANUS TOXOID; UNCLASSIFIED DRUG;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ARTICLE; CLINICAL ARTICLE; COMPETITIVE INHIBITION; CONTROLLED CLINICAL TRIAL; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VIVO STUDY; INHIBITION KINETICS; KIDNEY ALLOGRAFT; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; LIVING DONOR; MALE; MONOTHERAPY; PLASMA CELL; PLASMAPHERESIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEASOME INHIBITION; SENSITIZATION; TREATMENT RESPONSE;

ADULT; BORONIC ACIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GRAFT REJECTION; HUMANS; INCIDENCE; ISOANTIBODIES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PLASMA CELLS; PLASMA EXCHANGE; PROSPECTIVE STUDIES; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; TISSUE DONORS; TREATMENT OUTCOME;

EID: 79952188665     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3182081333     Document Type: Article

References (25)

1. Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969; 280: 735.
2. Lee P-C, Terasaki PI, Takemoto SK, et al. All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies. Transplantation 2003; 74: 1192.
3. Stegall MD, Gloor JM, Winters JL, et al. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 2006; 6: 346.
4. Manz RA, Thiel A, Radbruch A. Lifetime of plasma cells in the bone marrow. Nature 1997; 388: 133.
5. Slifka MK, Ahmed R. Long-lived plasma cells: A mechanism for maintaining persistent antibody production. Curr Opin Immunol 1998; 10: 252.
6. Ellyard JI, Avery DT, Phan TG, et al. Antigen-selected, immunoglobulin- secreting cells persist in human spleen and bone marrow. Blood 2004; 103: 3805.
7. Ramos EJ, Pollinger HS, Stegall MD, et al. The effect of desensitization protocols on human splenic B-cell populations in vivo. Am J Transplant 2007; 7: 402.
8. Perry DK, Pollinger HS, Burns JM, et al. Two novel assays of alloantibody- secreting cells demonstrating resistance to desensitization with IVIG and rATG. Am J Transplant 2008; 8: 133.
9. Perry DK, Burns JM, Pollinger HS, et al. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant 2009; 9: 201.
10. Neubert K, Meister S, Moser K, et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med 2008; 14: 748.
11. Meister S, Schubert U, Neubert K, et al. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res 2007; 67: 1783.
12. Lee A-H, Iwakashi NN, Anderson KC, et al. Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc Nat Acad Sci USA 2003; 100: 9946.
13. Sapaznikov A, Pewzner-Jung Y, Kalchenko V, et al. Perivascular clusters of dendritic cells provide critical survival signals to B cells in bone marrow niches. Nat Immunol 2008; 9: 388.
14. Nair RR, Tolentino J, Hazlhurst LA. The bone marrow microenvironment as a sanctuary for minimal residual disease in CML. Biochem Pharmacol 2010; 80: 602.
15. Fairfax KA, Kallies A, Nutt SL, et al. Plasma cell development: From B-cell subsets to long-term survival niches. Semin Immunol 2008; 20: 49.
16. Chtanova T, Tangye SG, Newton R, et al. T follicular helper cells express a distinctive transcriptional profile, reflecting their role as non-Th1/Th2 effector cells that provide help for B cells. J Immunol 2004; 173: 68.
17. Gelinck LB, Jol-vander Zijde CM, Jansen-Hoogendijk AM, et al. Restoration of the antibody response upon rabies vaccination in HIVinfected patients treated with HAART. AIDS 2009; 23: 2451.
18. Everly MJ, Everly JJ, Susskind B, et al. Bortezomib provides effective therapy for antibody and cell-mediated rejection. Transplantation 2008; 86: 1754.
19. Walsh RC, Everly JJ, Brailey P, et al. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection. Transplantation 2010; 89: 277.
20. Trivedi HL, Terasaki PI, Feroz A, et al. Abrogation of anti-HLA antibodies via proteasome inhibition. Transplantation 2009; 87: 1555.
21. Sberro-Soussan R, Zuber J, Suberbielle-Boissel C, et al. Boretzomib as the sole post-renal transplantation desensitization agent does not decrease donor-specific anti-HLA antibodies. Am J Transplant 2010; 10: 681.
22. Adeyi OA, Girnita Al, Howe J, et al. Serum analysis after transplant nephrectomy reveals restricted antibody specificity patterns against structurally defined HLA class I mismatches. Transplant Immunol 2005; 14: 52.
23. Hardy MA, Suciu-Foca N, Reed E, et al. Immunomodulation of kidney and heart transplants by anti-idiotypic antibodies. Ann Surg 1991; 214: 522.
24. Burns JM, Cornell LD, Perry DK, et al. Alloantibody levels and acute humoral rejection early after positive crossmatch kidney transplantation. Am J Transplant 2008; 8: 2684.
25. Warhman M, Haidinger M, Körmöczi GF, et al. Effect of the proteasome inhibitor bortezomib on humoral immunity in two presensitized renal transplant candidates. Transplantation 2010; 89: 1385; epub ahead of print.